Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Evaluating ethnic differences in the prescription of NSAIDs for chronic kidney disease: a cross-sectional survey of patients in general practice.

Hull S, Mathur R, Dreyer G, Yaqoob MM.

Br J Gen Pract. 2014 Jul;64(624):e448-55. doi: 10.3399/bjgp14X680557.

2.

Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.

Golder S, Loke YK, Bland M.

PLoS Med. 2011 May;8(5):e1001026. doi: 10.1371/journal.pmed.1001026. Review.

3.
4.

European Medicines Agency policies for clinical trials leave women unprotected.

Ruiz Cantero MT, Angeles Pardo M.

J Epidemiol Community Health. 2006 Nov;60(11):911-3. No abstract available.

5.

Complicity theory: an explanation for the 'coxib problem'?

Dieppe P.

J R Soc Med. 2006 Jun;99(6):273-4. No abstract available.

6.

Evaluating medical effectiveness for the california health benefits review program.

Luft HS, Rappaport KM, Yelin EH, Aubry WM.

Health Serv Res. 2006 Jun;41(3 Pt 2):1007-26.

8.

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs.

Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL; Intramuscular Methylprednisolone Study Group..

Ann Rheum Dis. 2005 Sep;64(9):1288-93.

9.

Lessons from the withdrawal of rofecoxib.

Dieppe PA, Ebrahim S, Martin RM, J√ľni P.

BMJ. 2004 Oct 16;329(7471):867-8. No abstract available.

10.
11.

Balancing benefits and harms in health care: ethical dimension was not discussed in theme issue.

Ashcroft RE.

BMJ. 2004 Aug 21;329(7463):458; discussion 458-9. No abstract available.

12.
Items per page

Supplemental Content

Support Center